Scientific work

Prof. Dr. Meral Beksaç

911 publications. The source of the information is stated next to each publication.

Back to profile

  1. Predisposing or Protective HLA Specificities Associated with the Development of Multiple Myeloma (MM)

    Clinical Lymphoma & Myeloma, 2009

    DOI 10.1016/s1557-9190(11)70687-4 Source: ORCID

  2. Quantification of mesenchymal stem cells in grafts adds to the benefits of haematopoietic stem cell and T-cell analysis in prediction of the duration of aplasia but not probability of acute graft-versus-host disease: preliminary results

    Bone Marrow Transplantation, 2009

    Source: ORCID

  3. Randomized comparison of bone marrow and peripheral blood stem cells for treatment of leukaemia - long-term follow-up results on survival, GvHD and late effects

    Bone Marrow Transplantation, 2009

    Source: ORCID

  4. Reduced-intensity Conditioning Allogeneic Stem Cell Transplantation in Myeloma: A Prospective Trial

    Clinical Lymphoma & Myeloma, 2009

    DOI 10.1016/s1557-9190(11)70446-2 Source: ORCID

  5. TRACKING OF DONOR TYPE GREN FLUORESCENT AND LUCIFERASE POSITIVE MARROW MONONUCLEAR OR MESENCHYMAL STEM CELLS IN POSTMORTEM SPINAL CORD HISTOPATHOLOGICAL SECTIONS FOR DETERMINATION OF REGENERATION IN A SPINAL CORD INJURY MODEL

    Haematologica, 2009

    Source: ORCID

  6. Tandem Autologous(ASCT)/Allogeneic Reduced Intensity Conditioning Transplantation (RIC) with Identical Sibling Donor Versus ASCT in Previously Untreated Multiple Myeloma (MM): Long Term Follow up of a Prospective Controlled Trial by the EBMT

    Blood, 2009

    DOI 10.1182/blood.v114.22.52.52 21 citations (OpenAlex) Source: ORCID

  7. The effect of rituximab in first line therapy to results of autologus haematopoietic stem cell transplantation in relapsed non-Hodgkin's lymphoma patients

    Bone Marrow Transplantation, 2009

    Source: ORCID

  8. Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndrome: A Retrospective Validation From a Single Centre.

    Blood, 2009

    DOI 10.1182/blood.v114.22.4846.4846 Source: OpenAlex

  9. Stress-Induced Release of Cortisol and Prolactin during Dilatation and Curettage under General and Local Anesthesia

    Neuropsychobiology, 2008

    DOI 10.1159/000118084 PMID 6493478 2 citations (Europe PMC) Source: OpenAlex

  10. Allogeneic haematopetic cell transplantation in elderly patients: validation of survival according to Sorror comorbidity index

    Bone Marrow Transplantation, 2008

    Source: ORCID

  11. Autologous stem cell transplantation (ASCT) vs ASCT followed by reduced-intensity conditioning allogeneic SCT with identical sibling donor in previously untreated multiple myeloma: preliminary analysis of a prospective controlled trial by the EBMT

    Bone Marrow Transplantation, 2008

    Source: ORCID

  12. COMPARATIVE ANALYSIS OF MESENCHYMAL STEM CELL CONTENT DETECTED BY FLOW CYTOMETRY IN UMBILICAL CORD BLOOD, G-CSF MOBILIZED PERIPHERAL BLOOD, ADULT AND PEDIATRIC BONE MARROW OF HEALTHY DONORS

    Haematologica, 2008

    Source: ORCID

  13. Cord blood banking

    Vox Sanguinis, 2008

    DOI 10.1111/j.1423-0410.2008.01106.x PMID 19138265 24 citations (Europe PMC) Open-access full textSource: ORCID

  14. Do the febrile neutropenic episodes during mobilisation have any effect on autologous stem cell collection yield in patients with myeloma and lymphoma?

    Bone Marrow Transplantation, 2008

    Source: ORCID

  15. FACTORS INVOLVED IN RESPONSE TO THALIDOMIDE IN MYELODYSPLASTIC SYNDROME: IMPACT OF HLA AND PROGNOSTIC FACTORS

    Haematologica, 2008

    Source: ORCID

  16. Familial multiple myeloma associated with disorders of chronic inflammation: First report from Turkey

    Clinical Lymphoma and Myeloma, 2008

    DOI 10.3816/clm.2008.n.033 PMID 18765313 4 citations (Europe PMC) Source: ORCID

  17. HLA Specificities and Predisposition to the Development of Multiple Myeloma (MM)

    Blood, 2008

    Source: ORCID

  18. HLA-A, -B, -C, -DR haplotypes, linkeage and frequencies observed in Ankara University, Turkey: a report from Tran

    Tissue Antigens, 2008

    Source: ORCID

  19. High Dose (HD-AraC) Vs Standard Dose Cytosine Arabinoside (SD-AraC) during Induction and Value of IL-2 during Maintenance in Acute Myelogenous Leukemia (AML): Impact of AraC Dose on Complete Remission Rate and Toxicity (Results on the first 1700 randomized patients of the AML-12 trial of EORTC and GIMEMA Leukemia Groups)

    Blood, 2008

    Source: ORCID

  20. Long Term Outcome and Late Effects in Patients Transplanted with Filgrastim-Mobilized Blood or Bone Marrow Treated in a Randomized Trial. A Study from the EBMT Late Effects Working Party

    Blood, 2008

    Source: ORCID

  21. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: An analysis of 10 549 patients from the International Myeloma Working Group

    Blood, 2008

    DOI 10.1182/blood-2007-03-081018 PMID 18268097 156 citations (Europe PMC) Open-access full textSource: ORCID

  22. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

    Haematologica, 2008

    DOI 10.3324/haematol.11080 PMID 18268286 367 citations (Europe PMC) Open-access full textSource: ORCID

  23. Response to induction, early mobilisation and pre-autologous transplant use of bortezomib and/or thalidomide prolong progression free and/or overall survival in myeloma

    Bone Marrow Transplantation, 2008

    Source: ORCID

  24. T-helper-1 (Th1) and Th2 cytokines after allogeneic hematopoietic stem cell transplantation (allo-HSCT)

    Turkish Journal of Hematology, 2008

    Source: ORCID

  25. THE IMPACT OF THE DISPARITIES OF SHORT TANDEM REPEATS (STR) BETWEEN DOONOR-RECIPIENT PAIR ON THE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (AHCT) OUTCOME

    Biology of Blood and Marrow Transplantation, 2008

    DOI 10.1016/j.bbmt.2007.12.311 Open-access full textSource: ORCID

  26. The evolving treatment paradigm of multiple myeloma: From past to present and future

    Turkish Journal of Hematology, 2008

    Source: ORCID

  27. The relation between the disparities of short tandem repeats between donor-recipient pair and the allogeneic haematopoietic cell transplantation outcome

    Bone Marrow Transplantation, 2008

    Source: ORCID

  28. Vitiligo after hematopoietic cell transplantation: Six cases and review of the literature

    Dermatology, 2008

    DOI 10.1159/000117705 PMID 18285686 29 citations (Europe PMC) Source: ORCID

  29. High Dose (HD-AraC) Vs Standard Dose Cytosine Arabinoside (SDAraC) during Induction and Value of IL-2 during Maintenance in Acute Myelogenous Leukemia (AML): Impact of AraC Dose on Complete Remission Rate and Toxicity (Results on the first 1700 randomized patients of the AML-12 trial of EORTC and GIMEMA Leukemia Groups)

    Blood, 2008

    DOI 10.1182/blood.v112.11.134.134 8 citations (OpenAlex) Source: OpenAlex

  30. Factors Involved in Response to Thalidomide in Myelodysplastic Syndrome: Impace of HLA and Prognostic Factors

    Blood, 2008

    DOI 10.1182/blood.v112.11.5079.5079 Source: OpenAlex

  31. Allogeneic hematopoietic cell transplantation in imatinib era: A single center comparative analysis of imatinib receiving patients to imatinib naive patients

    Biology of Blood and Marrow Transplantation, 2007

    Source: ORCID

  32. Amplitude of response, early mobilization (M) and pre-autologous transplant (ASCT) use of bortezomib (V) and/or thalidomide (T) are predictors of longer progression free (PFS) and/or overall survival (OS) in myeloma

    Blood, 2007

    DOI 10.1182/blood.v110.11.5096.5096 Source: ORCID

  33. Case matched comparison for analysing the impact of regimen intensity of allogeneic haematopoietic cell transplantation in chronic myeloid leukaemia

    Bone Marrow Transplantation, 2007

    Source: ORCID

  34. Clinical outcome following implantation of autologous bone marrow mononuclear cells into the traumatized spinal cord: 6-18 month follow-up results of four consecutive patients

    Bone Marrow Transplantation, 2007

    Source: ORCID

  35. Dna hyperploidy is associated with both high plasma cell percentage & high β2 microglobulin and impairs survival in myeloma patientstreated with or without transplantation

    Haematologica, 2007

    Source: ORCID

  36. Efficacy of bortezomib in combination chemotherapy on secondary plasma cell leukemia [6]

    Leukemia and Lymphoma, 2007

    DOI 10.1080/10428190701370597 PMID 17613776 8 citations (Europe PMC) Source: ORCID

  37. HLA typing with sequence-specific oligonucleotide primed PCR (PCR-SSO)and use of the Luminex technology.

    Methods in molecular medicine, 2007

    DOI 10.1007/978-1-59745-223-6_5 PMID 17666743 26 citations (Europe PMC) Source: ORCID

  38. HLA-DR15 and HLA-DR3 are observed more frequently among allo-transplanted compared to auto-transplanted or non-transplanted patients, a finding observed in myeloma, but not CML, cases from various countries

    Tissue Antigens, 2007

    Source: ORCID

  39. HemHLA (R) (Ankara, tr): a flexible software for HLA typing laboratories and registries that supports storage, transport and search functions on donor/recipient data

    Tissue Antigens, 2007

    Source: ORCID

  40. High CD95 expression of BAL lymphocytes predicts chronic course in patients with sarcoidosis

    Respirology, 2007

    DOI 10.1111/j.1440-1843.2007.01151.x PMID 17986116 9 citations (Europe PMC) Source: ORCID

  41. Identification of bone marrow derived nonhematopoietic cells by double labeling with immunohistochemistry and in situ hybridization.

    Methods in molecular medicine, 2007

    DOI 10.1007/978-1-59745-223-6_11 PMID 17666749 Source: ORCID

  42. Impact of HLA on availability of a donor, graft versus host disease frequency, and survival among 611 myeloma patients transplanted at three institutions from three continents

    Haematologica, 2007

    Source: ORCID

  43. Impact of histopathological subtype of cutaneous chronic GvHD on alloHSCT outcome: Iichenoid versus scleradermoid

    Bone Marrow Transplantation, 2007

    Source: ORCID

  44. P007 Both HLA DRB1*11 and DRB1*15 are observed more frequently among patients with myelodysplastic syndrome compared to healthy controls

    Leukemia Research, 2007

    DOI 10.1016/s0145-2126(07)70077-2 Source: ORCID

  45. PET/CT imaging in multiple myeloma-preliminary results

    European Journal of Nuclear Medicine and Molecular Imaging, 2007

    Source: ORCID

  46. Phosphorylated retinoblastoma expression by plasma cells is associated with a trend for advanced stages, refractoriness and shorter survival following chemotherapy in patients with newly diagnosed myeloma

    Haematologica, 2007

    Source: ORCID

  47. Report of the european myeloma network (EMN) workshop on multiparametric flow cytometry in multiple myeloma and related disorders

    Haematologica, 2007

    Source: ORCID

  48. Sequence-specific primed PCR (PCR-SSP) typing of HLA Class I and Class II alleles.

    Methods in molecular medicine, 2007

    DOI 10.1007/978-1-59745-223-6_4 PMID 17666742 4 citations (Europe PMC) Source: ORCID

  49. The conditioning regimen intensity of allogeneic hematopoietic cell transplantation (Allo-HCT) in chronic myeloid leukemia (CML): The historical case matched comparison of ablative versus reduced intensity regimen

    Biology of Blood and Marrow Transplantation, 2007

    DOI 10.1016/j.bbmt.2006.12.227 Open-access full textSource: ORCID

  50. The determination of leukemic phenotype and minimal residual disease in acute myeloid leukemia by using flow cytometry

    Haematologica, 2007

    Source: ORCID